$0.55
▲ +$0.02
(+3.77%)
Vol 423K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$12.8M
ROE
-224.8%
Margin
-313.8%
D/E
0.00
Beta
3.12
52W
$1–$5
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 60.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.46 | $-0.50 | $-0.04 |
| Sep 2025 | $-0.59 | $-0.49 | +$0.10 |
| Jun 2025 | $-0.91 | $-0.68 | +$0.23 |
| Mar 2025 | $-1.21 | $-1.25 | $-0.04 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $2.9M | $3.3M | $2.4M | $2.7M | $3.2M |
| Net Income | -$10.1M | -$9.6M | -$10.6M | -$8.6M | -$7.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -224.8% | -224.8% | -224.8% | -224.8% | -224.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -312.6% | -341.2% | -341.2% | -341.2% | -313.8% | -313.8% |
| Gross Margin | 99.4% | 99.4% | 99.4% | 99.4% | 99.5% | 99.5% |
| D/E Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 0.74 | 0.74 | 0.74 | 0.74 | 0.70 | 0.70 |
Key Ratios
ROA (TTM)
-106.4%
P/S (TTM)
1.10
P/B
3.8
EPS (TTM)
$-3.68
CF/Share
$-9.25
Rev Growth 3Y
+0.8%
52W High
$4.50
52W Low
$1.02
$1.02
52-Week Range
$4.50
Financial Health
Free Cash Flow
-$5.6M
Net Debt
-$7.1M
Cash
$9.1M
Total Debt
$2.0M
As of Sep 30, 2025
How does CRIS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CRIS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.1
▼
91%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
3.8
▲
55%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CRIS profitability vs Biotechnology peers
ROE
-224.8%
▼
234%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-313.8%
▼
9%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
99.5%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-106.4%
▼
128%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CRIS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
0.7
▼
84%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
3.1
▲
222%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CRIS fundamentals radar
CRIS
Peer median
Industry
CRIS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRIS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
DENTZER JAMES E
Chief Executive Officer · Mar 20
133333 shs
RUBIN MARC R
Director · Mar 20
26667 shs
HAMDY AHMED
Officer · Mar 20
66667 shs
DUVALL DIANTHA
Chief Financial Officer · Mar 20
66666 shs
ZUNG JONATHAN B PH.D.
Officer · Mar 20
66667 shs
Last 90 days
Top Holders
Top 5: 23.53%Bleichroeder LP
8.27%
$631K
Armistice Capital, LLC
6.43%
$491K
M28 Capital Management LP
3.79%
$289K
Vanguard Group Inc
2.67%
$203K
CM Management, LLC
2.37%
$181K
As of Dec 31, 2025
Latest News
High Taxes, Power Bill Crisis Send Maryland Gov. Moore's Poll Numbers To …
ZeroHedge · Apr 04
‘India is going to face a food crisis’: Farmers panic over fertiliser …
The Guardian · Apr 04
How sheltered really is the US from the Gulf oil supply crisis?
The Guardian · Apr 03
A day in the life of Asia’s fuel crisis
The Guardian · Apr 03
Putin To Saudi Crown Prince: Russia Ready To Do Everything To Stabilize …
ZeroHedge · Apr 03